{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Cancer Genomics"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001003351"],"host":["EGA"],"description":["EGA study EGAS00001003351"],"dataset_title":["Circulating tumour DNA abundance and potential utility in de novo metastatic prostate cancer"],"repository":["EGA"],"category":["restricted"],"name_synonyms":["(Deoxyribonucleotide)n+m, thymus nucleic acid, metastatic prostate cancer., DNS, metastatic prostate carcinoma, Deoxyribonucleic Acid, (Deoxyribonucleotide)n, DNAn+1, ds DNA, Desoxyribonukleinsaeure, Double-Stranded DNA, Double Stranded, (Deoxyribonucleotide)m, DNA, Deoxyribonucleic acid, deoxyribonucleic acids, DNAn, ds-DNA, prostate cancer metastatic, Double-Stranded, other neoplasm, desoxyribose nucleic acid, Deoxyribonucleic acids, prostate carcinoma metastatic"],"description_synonyms":["IPP2A2, Antemortem Diagnosis, DNS, insensitive, Prostate Neoplasms, (Deoxyribonucleotide)n, Plasmacytes, Neoplasms, Diagnosis, Deoxyribonucleic acids, PHAPII, 5730420M11Rik, Deoxyribonucleic Acid, sensitive, Prostatic Cancers, Mass, symptoms, Screening, cytopathology, Antemortem, Cancer of Prostate, sensitivity, Gonadectomies, Prostate Cancers, treatment, SET, thymus nucleic acid, simple tissue., Biopsies, TAF-I, ipp2a2, Tissue, Double Stranded, 2pp2a, Deoxyribonucleic acid, Diagnoses and Examinations, free, CG10574, DmelCG4299, allergic reaction, IGAAD, set, Prostatic Neoplasm, Cancer of the Prostate, 2PP2A, DmelCG10574, taf-ibeta, Clients, disease management, Therapies, dSET, dSet, Prostatic, Double-Stranded DNA, (Deoxyribonucleotide)m, deoxyribonucleic acids, DNAn, Plasma Cell, Diagnose, Cancer, hereditary prostate cancer, Therapy, phapii, Antemortem Diagnoses, screening, cancer of the prostate, Prostates, findings, effector B-cell, DNAn+1, familial, igaad, StF-IT-1, Double-Stranded, Client, Examination and Diagnoses, Cell, group, Diagnoses, (Deoxyribonucleotide)n+m, plasma B cell, Postmortem, Screenings, I-2PP2A, Mass Screenings, male prostate, Examinations and Diagnoses, Prostatic Cancer, Dm I-2, I2PP2A, Neoplasm, NOS, ds-DNA, Postmortem Diagnosis, desoxyribose nucleic acid, plasmocyte, Gonadectomy, Diagnoses and Examination, Plasma, Castrations, Postmortem Diagnoses, plasma B-cell, HLA-DR-associated protein II, histopathology, resistant, ensemble, DI-2, I-2Dm, effector B cell, signs, Cancers, CG4299, cancer of prostate, Treatments, Prostate Neoplasm, Plasmacyte, I-2PP1, dSET/TAF-Ibeta, metastatic, 2610030F17Rik, TAF-IBETA, Therapeutic, Patient, plasmacyte, ds DNA, Cells, Desoxyribonukleinsaeure, prostate cancer, PC, Treatment, TAF-Ibeta, DNA, biopsy, other neoplasm, AA407739, Prostate Cancer, i2pp2a, prostate, Prostate, prostata"],"additional_accession":[]},"is_claimable":false,"name":"Circulating tumour DNA abundance and potential utility in de novo metastatic prostate cancer","description":"Several systemic therapeutic options exist for metastatic castration sensitive prostate cancer (mCSPC). Circulating tumour DNA can profile metastatic castration resistant prostate cancer and influence treatment decisions, but remains untested in mCSPC. We set out to determine ctDNA abundance at de novo mCSPC diagnosis and whether ctDNA provides complementary clinically relevant information to a prostate biopsy. We collected and sequenced 77 plasma cell-free DNA samples from 53 newly diagnosed patients with mCSPC. Targeted sequencing was also performed on DNA from 48 diagnostic prostate tissue samples.","dates":{"updated":"2018-12-31 08:51:15"},"accession":"EGAS00001003351","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001004526","EGAC00001001099"]}}